

AD _____

Award Number: DAMD17-97-1-7155

TITLE: Estrogens, Microtubules and Aneuploidy: Mechanisms of
Mammary Gland Tumorigenesis

PRINCIPAL INVESTIGATOR: Gregory A. Reed, Ph.D.

CONTRACTING ORGANIZATION: University of Kansas Medical Center
Kansas City, Kansas 66160-7700

REPORT DATE: July 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20011127 056

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

| | | | | |
|--|---|--|---|----------------------------------|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE July 2001 | 3. REPORT TYPE AND DATES COVERED Annual (15 Jun 00 - 14 Jun 01) | |
| 4. TITLE AND SUBTITLE Estrogens, Microtubules and Aneuploidy: Mechanisms of Mammary Gland Tumorigenesis | | | 5. FUNDING NUMBERS DAMD17-97-1-7155 | |
| 6. AUTHOR(S) Gregory A. Reed, Ph.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Kansas Medical Center Kansas City, Kansas 66160-7700 E-Mail: greed@kumc.edu | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | | 12b. DISTRIBUTION CODE |
| 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) This project assesses possible mechanisms of tumorigenesis for estradiol and related estrogens. The intent is to use mammary epithelial cells (MEC) from rat strains which differ markedly in their susceptibility to estrogen carcinogenicity. The hypothesis to be tested is that MEC from the sensitive strain will show increased sensitivity to microtubule disruption and the induction of aneuploidy by estrogens than will the cells from the resistant strain. This hypothesis has not been tested in the past year, and the author has tried repeatedly to obtain authorization for a one year no-cost extension of the project. | | | | |
| 14. SUBJECT TERMS breast cancer, CDA award | | | | 15. NUMBER OF PAGES 27 |
| | | | | 16. PRICE CODE |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

| | |
|-----------------------------------|------------------------------|
| Cover..... | 1 |
| SF 298..... | 2 |
| Table of Contents..... | 3 |
| Introduction..... | 4 |
| Body..... | 4 - 6 |
| Key Research Accomplishments..... | 6 |
| Reportable Outcomes..... | 6 |
| Conclusions..... | 6 |
| References..... | 6 |
| Appendices..... | 7 – 15, plus two reprints |

Introduction

Estrogen exposure represents one of the few clear risk factors for breast cancer in humans. This potential risk is underscored by the finding that both natural and synthetic estrogens are mammary carcinogens in animal models. Despite this clear association between estrogens and breast cancer, the mechanism of tumorigenesis by these agents has not been established. This project will test the hypothesis that estrogens or their metabolites, via covalent binding, are specific disruptors of mitotic microtubules in mammary epithelial cells, and that the resulting interference with mitosis causes aneuploidy. Moreover, the induction of non-random changes in ploidy represents a key step in the malignant transformation of mammary epithelial cells. To test this hypothesis, we will study the metabolism and effects of the mammary carcinogen estradiol (E2), in liver microsomes and in rat mammary epithelial cell lines (RMEC). Microsomes and mammary epithelial cells will be isolated from female ACI, Sprague-Dawley, and Copenhagen (COP) rats. The former strain is extremely sensitive to estrogens as mammary carcinogens, whereas the Sprague-Dawley and COP strains are relatively resistant to estrogens. The concentration- and time-dependence of metabolism and the covalent modification of proteins will be determined for E2 in preparations from each rat strain, as will the specific covalent modification of tubulin subunits. These chemical endpoints will be compared with the determinations of several cellular changes in response to each of the compounds. Effects on cell proliferation will be assessed by immunohistochemical analysis of the proliferation-specific nuclear antigen PCNA (19A2). Effects on the integrity of microtubules (mitotic spindles) also will be determined immunohistochemically using anti-rat tubulin antibodies. Finally, aneuploidy will be analyzed by flow cytometry. These studies of the effects of the compounds on subcellular structure and function constitute a step-wise examination of the proposed mechanism of action for carcinogenic estrogens. Induction of proliferation will be used as a general index of estrogenicity. The effects on microtubules, however, begin to explore the link between covalent modification of tubulin in a target cell for carcinogenicity of these compounds and the disruption of mitosis. If the covalent modification of tubulin, the disruption of microtubules, and the induction of aneuploidy follow the same time- and concentration-dependence then a strong mechanistic link will be forged. This will support future studies on the induction of aneuploidy by estrogens in mammary epithelial cells *in vivo*.

Body

This project has not been active during the period of August 2000 – June 2001. The loss of all technical support combined with the increased teaching and administrative loads resulting from a significant decrease in the departmental faculty roster have prevented active research. One obstacle has now been overcome, as evidenced by the assignment of a half-time research assistant to this project. The second obstacle remains, but the adaptation to this higher teaching and administrative load will allow for sufficient research time and effort to finish this project.

Recognizing the inactivity on this project, I began requests in January 2001 for a one year extension in time without additional budget. Despite several email requests and a formal letter of request sent by Federal Express to my project officer (included as an Appendix) I have received

no response from USAMRMC. I am now once again requesting this one year extension. During this period the project goals can be met.

The laboratory of Jim Shull at the Eppley Cancer Center in Omaha has isolated and characterized spontaneously immortalized non-transformed epithelial cell lines from the mammary glands of the ACI rat and from its' E2-resistant parental strain, the Copenhagen rat (COP). These cells grow readily in low- or no-serum media and retain much of their epithelial morphology and behavior. We propose to use this established, robust cell system for our remaining studies.

The use of the mammary epithelial cell lines retains the essential feature of the original experimental design, namely to study estrogens in target cell populations from strains sensitive to and resistant to the carcinogenic effects of estrogens. In fact, using RMEC derived from the Copenhagen rat, an estrogen-resistant parental strain for the ACI hybrid, we have arguably a closer match between the two strains with the exception of the marked difference in response to estrogens, and thus a cleaner system for sorting out key mechanistic steps related to carcinogenesis. The use of the cell lines also clearly will bypass our failure to produce viable early passage cultures of these cells. The major drawback to the use of these cell lines is the assumption that, like virtually all epithelial cells, they will have ceased expression of cytochrome P450s after so many passages. We will experimentally verify this by examination of E2 metabolism, but we also will press ahead with investigations of how cells from the two strains respond to E2 and its metabolites.

First, we will assess the proliferative effect of E2, estrone (E1), estriol (E3), 4-hydroxy-E2, 2-hydroxy-E2, 4-hydroxy-E1, 2-hydroxy-E1, 4-methoxy-E2, and 2-methoxy-E2 on these cells. Cultures in serum-free medium will be treated with each of these estrogens at concentrations between 0.1 and 10,000 nM. Cell samples will be taken at 6, 12, 24, 48, and 72 hrs and viable cell numbers estimated by tetrazolium dye reduction to determine the effects of each steroid on proliferation rate. These findings will be confirmed at key concentrations and time points by immunohistochemical determination of proliferative fraction, using the 19A2 nuclear antigen as the indicator of proliferation.

The next series of experiments will utilize anti-tubulin antibodies to characterize the effects of these estrogens on cytoskeletal structures, particularly the mitotic microtubules. Cells will be treated with the estrogens over the same concentration range as noted above, and cells then will be fixed and stained with fluorescent anti-tubulin. A second staining with anti-actin will discriminate between effects on microtubules and more generalized anti-cytoskeletal effects. Obviously anti-mitotic effects only may be seen in cells which are actively proliferating. If the proliferative fraction of cells is too low, we will employ hydroxyurea treatment to synchronize cells, and then release them immediately prior to addition of the appropriate estrogen.

Finally, we will examine the ploidy of control and estrogen-treated RMEC using flow cytometry. The original experimental design proposed to examine ploidy and chromosomal aberrations using whole chromosome painting with various fluorescent probes, analyzed using the Vysis computerized imaging system. This approach has been replaced for two reasons. The first is the short time left during this award, which would preclude learning and validating this approach.

Second, the fluorescent oligonucleotide probe set for the rat genome, required for this analysis, has not yet been developed. This was to have proceeded to completion prior to its required use in this project, but that has not yet occurred.

Key Research Accomplishments

None.

Reportable Outcomes

Publications

Reed, G.A., Wilson, A.M., and Padgitt, J.K.: Estradiol metabolism by rat liver microsomes from strains differing in susceptibility to mammary carcinogenesis. In: *Hormonal Carcinogenesis III* (J.J. Li, J.R. Daling, S.A. Li, eds.), pp. 451-455, Springer-Verlag, New York, 2001.

Wilson, A.M. and Reed, G.A.: Predominant 4-hydroxylation of estradiol by constitutive cytochrome P450s in the ACI rat liver. *Carcinogenesis* **22**: 257-263, 2001.

Degree Awarded

Wilson, Angela M., M.S. in Pharmacology, Department of Pharmacology, Toxicology, and Therapeutics, School of Medicine, University of Kansas. Defended August 31, 2000.

Conclusions

As detailed above, personnel changes and an increase in non-research responsibilities prevented any meaningful progress on this project in the past year. Those situations now have been partially resolved, and it is expected that significant time and effort can be applied to this project in the requested one year extension period. The receipt of formal authorization for both the revised Statement of Work and for this one year extension would be greatly appreciated.

References

None.

Appendices

Correspondence Requesting No-Cost Extension of Time

2 Reprints

From: Greg Reed
To: Judy.Pawlus@det.amedd.army.mil
Date: 2/9/01 10:23AM
Subject: DAMD17-97-1-7155

Dear Ms. Pawlus:

I would like to request a one year extension of time, without additional budget, for my Breast Cancer Research project. Personnel problems have prevented significant progress within the last nine months. Those problems have been resolved, and the requested extension would allow for the completion of the project. Please advise me of the proper contact person to address with this request, and any additional information you can provide regarding the format or content of this request.

Thank you for your assistance.

Gregory A. Reed, Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics
University of Kansas Medical Center
(913)588-7513; FAX (913)588-7501
greed@kumc.edu

From: "Pawlus, Judy K Ms USAMRMC" <Judy.Pawlus@DET.AMEDD.ARMY.MIL>
To: "Lowery, Cheryl A Ms USAMRAA" <Cheryl.Lowery@DET.AMEDD.ARMY.MIL>
Date: 2/9/01 10:25AM
Subject: FW: DAMD17-97-1-7155

Cheryl, please respond to PI. Thank you.

-----Original Message-----

From: Greg Reed [mailto:greed@kumc.edu]
Sent: Friday, February 09, 2001 11:23 AM
To: Judy.Pawlus@det.amedd.army.mil
Subject: DAMD17-97-1-7155

Dear Ms. Pawlus:

I would like to request a one year extension of time, without additional budget, for my Breast Cancer Research project. Personnel problems have prevented significant progress within the last nine months. Those problems have been resolved, and the requested extension would allow for the completion of the project. Please advise me of the proper contact person to address with this request, and any additional information you can provide regarding the format or content of this request.

Thank you for your assistance.

Gregory A. Reed, Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics
University of Kansas Medical Center
(913)588-7513; FAX (913)588-7501
greed@kumc.edu

CC: "greed@kumc.edu" <greed@kumc.edu>

From: Greg Reed <greed@kumc.edu>
To: "Lowery, Cheryl A Ms USAMRAA" <Cheryl.Lowery@DET.AMEDD.ARMY.MIL>
Date: 2/21/01 2:56PM
Subject: DAMD17-97-1-7155

Ms. Lowery:

I am hoping to hear from you soon regarding my request (forwarded to you by Judy Pawlus on 2/9/01) for a one year extension of time without additional budget for this BCRP award.

Thank you for your attention to this matter.

Gregory A. Reed, Ph.D.
University of Kansas Medical Center

From: Greg Reed <greed@kumc.edu>
To: <Cheryl.Lowery@det.amedd.army.mil>
Date: 3/27/01 10:57AM
Subject: Fwd: DAMD17-97-1-7155

Ms. Lowery:

It has been almost two months since I inquired about requesting a no-cost extension on my BCRP award. The original deadline on this project is less than three months away. I need to find out as soon as possible whether or not this extension will be allowed. Please advise me on the status of this request.

Thank you

Gregory Reed, Ph.D.

From: "Lowery, Cheryl A Ms USAMRAA" <Cheryl.Lowery@DET.AMEDD.ARMY.MIL>
To: 'Greg Reed' <greed@kumc.edu>
Date: 3/29/01 2:32PM
Subject: RE: DAMD17-97-1-7155

Dr. Reed,

Thanks for your email. Unfortunately, I do not remember receiving your request for a no-cost extension.

I recommend you resubmit your request to Ms. Blossom Widder, at the address following my name. The request should be signed by your business office representative who has authority to bind your organization in legal grants and contracts.

Due to our recent reorganization, your grant has been reassigned to Ms. Widder, Contract Specialist. She can be contacted at (301)619-7143 (Voice), (301)619-4084 (Fax) or blossom.widder@amedd.army.mil (email)

Cheryl Lowery
Contract Specialist
U.S. Army Medical Research Acquisition
Activity
820 Chandler Street
Fort Detrick, MD 21702-5014
Telephone: 301-619-7150
FAX: 301-619-2254
Email: cheryl.lowery@amedd.army.mil

CC: "Pawlus, Judy K Ms USAMRMC" <Judy.Pawlus@DET.AMEDD.ARMY.MIL>, "Widder, Blossom J Ms USAMRAA" <Blossom.Widder@DET.AMEDD.ARMY.MIL>, "Herndon, Dana L Ms USAMRAA" <Dana.Herndon@DET.AMEDD.ARMY.MIL>, "Lowery, Cheryl A Ms USAMRAA" <Cheryl.Lowery@DET.AMEDD.ARMY.MIL>

April 4, 2001

Ms. Blossom Widder, Contract Specialist
U.S. Army Medical Research Acquisition
Activity
820 Chandler Street
Fort Detrick, MD 21702-5014

Dear Ms. Widder:

I would like to request a one year extension of time, without additional budget, for my Breast Cancer Research project, DAMD 17-1-97-7155. Personnel problems have prevented any significant progress within the last nine months. Those problems have been resolved, and the requested extension would allow for the completion of the project within the requested extension period. These requested changes in time line are detailed in the attached Proposed Statement of Work. Please advise me if any additional information is required to process this request.

Thank you for your assistance.

Sincerely yours,



Gregory A. Reed, Ph.D.
Principal Investigator



K. M. A. Welch, M.D.
Vice Chancellor for Research

PROPOSED STATEMENT OF WORK

Aim 1.

| | |
|---|----------------|
| Task 1. Establish radiometric HPLC assay for estradiol (E2) metabolism | Done |
| Task 2. Establish radiometric HPLC assay for 7,12-dimethylbenz[a]anthracene (DMBA) metabolism | Done |
| Task 3. Characterize E2 metabolism in ACI and SD RLM | Done |
| Task 4. Characterize DMBA metabolism by ACI and SD RLM | Delete |
| Task 5. Optimize culture conditions for ACI and COP-derived rat mammary epithelial cell lines (RMEC) | Months 48 - 49 |
| Task 6. Characterize E2 metabolism by RMEC from ACI and SD rats | Delete |
| Task 7. Characterize DMBA metabolism by ACI and SD RMEC | Delete |
| Task 8. Characterize covalent modification of ACI and COP RMEC proteins by E2 | Months 51 - 55 |
| Task 9. Characterize covalent modification of nuclear DNA in ACI and COP RMEC by E2 | Delete |

Aim 2.

| | |
|---|----------------|
| Task 1. Optimize immunochemical methods for examination of mitotic microtubule integrity in ACI and COP RMEC | Months 50 - 51 |
| Task 2. Determine concentration dependence of effects of E2 on microtubule integrity in ACI and COP RMEC | Months 52 - 54 |
| Task 3. Determine time dependence of effects of E2 on microtubule integrity in ACI and COP RMEC | Month 55 |

Aim 3.

| | |
|--|----------------|
| Task 1. Learn and optimize procedures for detecting aneuploidy in ACI and COP RMEC | Month 56 |
| Task 2. Determine the concentration dependence of the effects of E2 on ploidy in RMEC | Months 57 - 58 |
| Task 3. Determine the time dependence of the effects of E2 on ploidy in RMEC | Months 58-59 |

Final report

Month 60

Estradiol Metabolism by Rat Liver Microsomes from Strains Differing in Susceptibility to Mammary Carcinogenesis

Gregory A. Reed, Angela M. Wilson, and Janette K. Padgitt

Summary

Rat strains are known to differ markedly in their susceptibility to estrogen (E)-induced mammary tumors. Specifically, the ACI strain is extremely sensitive to Es, whereas the Sprague-Dawley (SD) strain is relatively resistant. We have compared the metabolism of estradiol (E_2) by liver microsomes from these two rat strains. Both strains exhibit hydroxysteroid dehydrogenase activity, with estrone (E_1) being the major product at E_2 concentrations above 1 μ M. Some A-ring hydroxylation also is seen. As the E_2 concentration is decreased, however, hydroxylation becomes a more dominant pathway for both strains. In the SD preparations this still yields E_1 as the major product. ACI liver, however, produces primarily hydroxylated- E_2 at these concentrations. This difference is most apparent at E_2 concentrations below 100 nM. This difference in the disposition of E_2 and its being most pronounced at E_2 concentrations nearing the physiological range, suggest that this difference may contribute to the relative sensitivity of these strains to E_2 carcinogenicity.

Introduction

The identification of carcinogenic risks may be derived from two complementary approaches: the first is epidemiological analysis of human populations, while the second is by extrapolation from controlled exposure studies with experimental animals. The association between Es and breast cancer has been supported by ample data from both approaches. Despite the clear association between Es and breast cancer, the mechanisms involved in this effect are not clear. A pronounced strain difference in sensitivity to mammary carcinogenesis by Es provides an opportunity to identify key mechanistic features of the process. The

ACI rat is sensitive to E_s as mammary carcinogens (1-4). Sprague-Dawley rats, in contrast, are relatively resistant to E carcinogenicity (2,5). By comparing E metabolism and resultant effects in the two strains it not only is possible to look for differences in metabolism and responses, but also to try and correlate these responses with susceptibility to carcinogenesis. The examination of estradiol (E_2) metabolism by liver microsomal preparations from these two strains represents the first step in these comparative studies.

Materials and Methods

Female Sprague-Dawley and ACI rats, 6 to 7 weeks old, were purchased from Harlan Laboratories. The livers were homogenized and microsomes prepared by differential centrifugation. Microsomal pellets were resuspended in phosphate- $MgCl_2$ buffer, pH 7.4, and stored at $-80^\circ C$.

$[^3H]-E_2$ was incubated with RLM (1 mg protein/ml) in 50mM Tris-HCl buffer, pH 7.4, containing 5 mM $MgCl_2$, 5 mM glucose-6-phosphate, and 1 mM ascorbate at $37^\circ C$. The NADPH generating system, where noted, included 1 U/ml glucose-6-phosphate dehydrogenase and was initiated by the addition of 1 mM NADP. Reactions with NADP or NAD as cofactors were initiated by the addition of these compounds, again to a final concentration of 1 mM. Incubations were continued for 10 to 60 min, as indicated, depending on substrate concentration. The reaction was stopped by the rapid extraction with 2 x 3 vol of ethyl acetate. The combined extracts were evaporated under vacuum, and the residue dissolved in the initial acetonitrile-methanol-water-acetic acid mix of the HPLC elution.

Separation of metabolites was performed on a Supelcosil C18 column (5 μ , 4.6 mm x 25 cm) at $30^\circ C$ using a gradient of acetonitrile, methanol, water, and 0.1% acetic acid (6). Unlabeled metabolite standards were detected by monitoring absorbance at 280 nm, whereas labeled metabolites were detected by a Packard Flo-One Beta detector with Ultima Flo M liquid scintillant.

Results

Liver microsomal preparations from female ACI and SD rats both catalyze extensive NADPH-dependent metabolism of E_2 . Oxidation of E_2 to E_1 and aromatic hydroxylation of E_2 were the only products observed with these preparations. Maximal rates of E_1 formation exceed 300 pmol $mg^{-1} min^{-1}$ in both strains, whereas maximal rates of aromatic hydroxylation are greater than 6 pmol $mg^{-1} min^{-1}$ in SD microsomes and 30 pmol $mg^{-1} min^{-1}$ in ACI liver microsomes. Extensive metabolism was observed not only at the commonly used micromolar concentrations of E_2 (7-10), but at substrate concentrations as low as 3 nM.

Although the metabolite profiles derived from the two strains are nearly identical at high substrate concentrations, a pronounced divergence emerges as the E_2 concentration drops below 1 μM (Figure 1). For both strains, aromatic hydroxylation becomes more pronounced as the E_2 concentration is decreased, but this shift is far more extensive in the ACI rat. As shown, at 100 nM E_2 aromatic hydroxylation to yield catechol Es becomes the dominant pathway for E_2 oxidation, comprising 73% of total metabolism. In the SD rat preparation, however, the fraction of metabolism resulting from aromatic hydroxylation only reaches 36% of the total. An additional 16% of the metabolites produced by the SD rat are catechol E_1 derivatives, which have undergone both 17β -dehydrogenation but also aromatic hydroxylation. Even combining the E_1 and E_2 catechol metabolites still only comprises 52% of total metabolism, as compared to the 73% catechols formed by the ACI liver microsomes under these same conditions.




Figure 1. Product Distribution from E_2 Oxidation by ACI and SD Rat Liver Microsomes: Effect of Substrate Concentration. Indicated concentrations of [^3H]- E_2 were incubated with 1 mg/ml microsomal protein with an NADPH generating system for 20 minutes. Extraction and analysis were as described. All data represent mean \pm standard deviation from triplicate incubations. A, ACI rat, 100 nM E_2 ; B, ACI rat, 30 μM E_2 ; C, SD rat, 100 nM E_2 ; D, SD rat, 30 μM E_2 .

The formation of hydroxylated products is assumed to be a cytochrome P450-dependent reaction, and thus NADPH-dependent, whereas the conversion to E_1 is a dehydrogenation which may utilize either NAD or NADP as a cofactor. This is borne out by the cofactor specificity demonstrated in Table 1. With the active glucose-6-phosphate dehydrogenase generating system maintaining most NADPH in the reduced form, fully 75% of E_2 metabolism is by hydroxylation, rather than dehydrogenation. The use of NADP, without the generating system

for reduction of the cofactor, results in a 3.5-fold increase in the rate of dehydrogenation to E_1 , and a 70% decrease in aromatic hydroxylation. The residual hydroxylation presumably results from reduction of NADP via the 17β -hydroxysteroid dehydrogenase reaction. Finally, when NAD is added as the cofactor, which is fully active as a 17β -hydroxysteroid dehydrogenase cofactor but inactive as a cytochrome P450 cofactor in either its oxidized or reduced form, no hydroxylation is observed and 100% of the E_2 is converted to E_1 . These cofactor studies clearly support the assignment of E_1 formation to 17β -hydroxysteroid dehydrogenase and the aromatic hydroxylation as a cytochrome P450-dependent reaction.

Table 1. Cofactor effect on E_2 oxidation by ACI rat liver microsomes.

| <u>Cofactor</u> | <u>Aromatic Hydroxylation</u> | <u>Dehydrogenation</u> |
|-------------------------|--|---|
| NADPH generating system | $25.8 \pm 1.1 \text{ pmol mg}^{-1} \text{ min}^{-1}$ | $8.7 \pm 2.2 \text{ pmol mg}^{-1} \text{ min}^{-1}$ |
| NADP | 6.3 ± 0.8 | 20.5 ± 0.5 |
| NAD | 0 | 50 ± 0 |

1 μM E_2 was incubated for 20 minutes with 1 mg/ml microsomal protein and either the NADPH generating system or with 1 mM NADP or NAD. Extraction and analysis were as described in Materials and Methods. Results are means \pm standard deviation from triplicate incubations.

Conclusions

1. Rat liver microsomes efficiently oxidize E_2 at concentrations as low as 3 nM.
2. 17β -Hydroxysteroid dehydrogenase is a relatively low affinity but high capacity system for E_2 oxidation in RLM. Cytochrome P450-dependent aromatic hydroxylation of E_2 is a relatively high affinity but low capacity system for E_2 oxidation in RLM.
3. RLM from the female ACI rat differ from those from other rat strains in that aromatic hydroxylation of E_2 is more dominant than it is in the SD rat.

Acknowledgment

This work was supported by DAMD17-97-1-7155 and ES-07079.

References

1. Dunning WF, Curtis MR (1952) The incidence of diethylstilbestrol-induced cancer in reciprocal F1 hybrids obtained from crosses between rats of inbred lines that are susceptible and resistant to the induction of mammary cancer by this agent. *Cancer Res* 12: 702-706.
2. Stone JP, Holtzman S, Shellabarger CJ (1979) Neoplastic responses and correlated plasma prolactin levels in diethylstilbestrol-treated ACI and Sprague-Dawley rats. *Cancer Res* 39: 773-778.
3. Shellabarger CJ, McKnight B, Stone JP et al (1980) Interaction of dimethylbenzanthracene and diethylstilbestrol on mammary adenocarcinoma formation in female ACI rats. *Cancer Res* 40: 1808-1811.
4. Shull JD, Spady TJ, Snyder MC et al (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17β -estradiol rapidly develop mammary carcinoma. *Carcinogenesis* 18: 1595-1601.
5. Sydnor KI, Butenandt O, Brillantes FP et al (1962) Race-strain factor related to hydrocarbon-induced mammary cancer in rats. *J Natl Cancer Inst* 29: 805-814.
6. Brueggemeier, RW, personal communication.
7. Dannan GA, Porubek DJ, Nelson SD et al (1986) 17β -Estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: Roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy and hormone replacement. *Endocrinology* 118: 1952-1960.
8. Watanabe K, Takanishi K, Imaoka S et al (1991) Comparison of cytochrome P-450 species which catalyze the hydroxylations of the aromatic ring of estradiol and estradiol 17-sulfate. *J Steroid Biochem Molec Biol* 38: 737-743.
9. Kerlan V, Dreano Y, Bercovici JP et al (1992) Nature of the cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. *Biochem Pharmacol* 44: 1745-1756.
10. Suchar LA, Chang RL, Thomas PE et al (1996) Effects of phenobarbital, dexamethasone, and 3-methylcholanthrene administration on the metabolism of 17β -estradiol by liver microsomes from female rats. *Endocrinology* 137: 663-676.

Predominant 4-hydroxylation of estradiol by constitutive cytochrome P450s in the female ACI rat liver

Angela M. Wilson and Gregory A. Reed¹

Department of Pharmacology, Toxicology and Therapeutics and Kansas Cancer Institute, University of Kansas Medical Center, Kansas City, KS 66160-7417, USA

¹To whom correspondence should be addressed at: Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160-7417, USA
Email: greed@kumc.edu

The ACI rat is extremely sensitive to estrogens as mammary carcinogens, whereas the Sprague–Dawley strain is relatively resistant. Comparison of the disposition and effects of estrogens in these two strains should provide insights into the mechanisms of estrogen carcinogenicity. We have begun this investigation by comparing the metabolism of [³H]17 β -estradiol (E2) by liver microsomes prepared from female rats from each strain. Both strains produce estrone (E1) as the major product at E2 concentrations >1 μ M, with smaller amounts of 2-hydroxy-E2 formed. As the E2 concentration is decreased, however, aromatic hydroxylation becomes a more dominant pathway for both strains. At starting E2 concentrations as low as 3 nM, Sprague–Dawley liver microsomes produced comparable yields of 2-hydroxy-E2 and E1. In contrast, ACI liver microsomes yielded a profound shift to aromatic hydroxylation as the dominant pathway as E2 concentrations dropped below 1 μ M, and this shift reflected the production of 4-hydroxy-E2 as the predominant product. The apparent K_m for 4-hydroxylation of E2 is <0.8 μ M, as opposed to ~4 μ M for 2-hydroxylation, suggesting that different cytochrome P450s (CYPs) are responsible. Western immunoblotting of the liver microsomal preparations from ACI and Sprague–Dawley rats for CYPs known to catalyze 2- and 4-hydroxylation of E2 revealed that both strains contained comparable amounts of CYP 2B1/2 and 3A1/2, but no detectable amounts of CYP 1B1, the proposed E2 4-hydroxylase. Although this enzyme is not a constitutive CYP in Sprague–Dawley rat liver, its presence in ACI liver could provide a ready explanation for the predominance of 4-hydroxy-E2 as a product. The identity of the estradiol 4-hydroxylase in ACI rat liver and the role of this unique reaction in the heightened sensitivity to E2 carcinogenicity remain to be elucidated.

Introduction

Estrogens are risk factors for breast cancer in humans. Epidemiological evidence indicates that an increase in level or duration of exposure to 17 β -estradiol (E2) and estrone (E1)

is associated with an increased incidence of breast cancer (1,2). Early menarche and late menopause are risk factors which increase duration of exposure to endogenous estrogens (3). Interruption of normal estrogen levels during pregnancy decreases estrogen exposure, thus late first full-term pregnancy and nulliparity increase a woman's chance of developing breast cancer (2,4–7). In addition, long-term use of hormone replacement therapies increases breast cancer risk due to an increase in the level of exposure and the duration of exposure to estrogens (1,7).

Animal studies provide more direct and quantifiable evidence for a causal role of estrogens in tumorigenesis (reviewed in refs 8,9). E1, E2 and the stilbene estrogen diethylstilbestrol induce mammary gland tumors in both rats and mice and estriol (E3) is also a mammary carcinogen in mice. The synthetic steroids norethynodrel and mestranol are mammary carcinogens in rats and dogs, respectively. In addition to these effects in mammary gland, estrogens are also carcinogenic in the liver, kidney, pituitary and various organs of the genitourinary tract of several species (10–12). Induction of tumors in multiple tissues and species strongly supports the IARC classification of estrogens as human carcinogens (13).

Although estrogens are known mammary carcinogens in animals and humans, the mechanisms of carcinogenesis are not clear. One proposed mechanism is based on the mitogenic action of estrogens in hormone-specific tissues (i.e. uterus and breast) mediated via estrogen receptors (2,8,14). With longer periods of enhanced proliferation there is an increased chance of mutations. Another mechanism has been proposed in which estrogens act as direct genotoxic carcinogens (15). Estrogen metabolites are able to covalently bind to DNA and the resulting modified sites in DNA are proposed to be pre-mutagenic lesions (11,16). The third proposed mechanism of E2 carcinogenicity is that estrogens or their metabolites are indirectly genotoxic. Reactive oxygen species, generated by redox cycling of estrogen metabolites, such as the catechols and hydroquinones, are suggested to be DNA damaging. This is thought to occur by oxidation or hydroxylation of the DNA to produce pre-mutagenic lesions which can lead to mutations (17,18). Finally, an epigenetic mechanism has been proposed based on the induction of aneuploidy which is concurrent with the emergence of cell transformation (19–21).

Determination of the primary mechanism of estrogen carcinogenicity will require an appropriate model system. The rat provides an excellent model for mammary carcinogenesis based on a low spontaneous tumor incidence and efficient induction of tumors by chemical agents (8,9). In addition, chemically induced rat mammary tumors clearly resemble human breast tumors based on their similar morphology and on the high degree of estrogen dependence seen in both rat and human tumors (reviewed in ref. 9). What is even more striking is the pronounced strain difference in rat sensitivities to mammary carcinogenicity. ACI rats are extremely sensitive to estrogens as mammary carcinogens, developing palpable

Abbreviations: CE1, 2/4-hydroxyestrone; COMT, catechol *O*-methyltransferase; CYP, cytochrome P450; DMBA, 7,12-dimethylbenz[*a*]anthracene; E1 estrone; E2, 17 β -estradiol; E3, estriol; 17 β -HSD, 17 β -hydroxysteroid dehydrogenase; 2-OH-E1, 2-hydroxyestrone; 4-OH-E1, 4-hydroxyestrone; 2-OH-E2, 2-hydroxyestradiol; 4-OH-E2, 4-hydroxyestradiol; 6 α -OH-E2, 6 α -hydroxyestradiol; RLM, rat liver microsomes.

tumors after 3 months treatment with E2 and 100% mammary tumor incidence after 6 months treatment (10,22). Sprague-Dawley rats, however, are much less sensitive to estrogens, exhibiting no mammary tumors after 7 months treatment (23,24). This strain difference in susceptibilities to mammary carcinogenicity is apparently specific for estrogens as causative agents. ACI rats are less sensitive to induction of mammary tumors by 7,12-dimethylbenz[*a*]anthracene (DMBA), a known mammary carcinogen, than are Sprague-Dawley rats. In fact, 100% of Sprague-Dawley rats treated with DMBA develop mammary tumors within a few weeks (25), whereas, only 30% of ACI rats develop mammary tumors after 8.5 months treatment. ACI rats are relatively insensitive to other genotoxic mammary carcinogens as well (26,27). This unique strain difference, in which the ACI rat is specifically more sensitive to estrogens as mammary carcinogens, presents an invaluable tool for determining the key mechanistic steps of E2 carcinogenicity.

Sprague-Dawley rats and ACI rats differ markedly in their responses to E2 with regard to mammary tumorigenesis. These differences could be due to differences in E2 pharmacodynamics, pharmacokinetics or both. By careful comparison of the interactions between E2 and the cells and tissues from these two strains we may dissect out critical processes which underlie the pronounced difference in susceptibility to tumor induction. These critical differences may also illuminate the major mechanism involved in estrogen carcinogenicity in the mammary gland. We have begun by comparing the metabolism of E2 by liver microsomes from the two strains. Although hepatic metabolism may not play as central a role in the mammary effects of E2 as target tissue metabolism, we nonetheless consider the characterization of hepatic E2 metabolism to be a logical first step in comparing these strains and their overall response to E2. We have observed quantitative and qualitative differences in E2 metabolism in ACI and Sprague-Dawley liver microsomes. The differences in hepatic metabolism of E2 between the two strains of rats may be the first step in elucidating the key differences affecting susceptibility to mammary carcinogenesis.

Materials and methods

Animals and chemicals

Sexually immature (6–7-week-old) and sexually mature (12–14-week-old) female Sprague-Dawley and ACI rats were purchased from Harlan Laboratories (Indianapolis, IN). [2,4,6,7-³H]E2 (72 Ci/mmol) and [4-¹⁴C]E2 (54.1 mCi/mmol) were products of New England Nuclear (Boston, MA). E2, E1, 2-hydroxyestradiol (2-OH-E2), 4-hydroxyestradiol (4-OH-E2), E3, 2-hydroxyestrone (2-OH-E1), 4-hydroxyestrone (4-OH-E1), 6 α -hydroxyestradiol (6 α -OH-E2), clotrimazole and all other substrates, enzymes and cofactors were from Sigma Chemical Co. (St Louis, MO). All solvents and reagent chemicals were of HPLC grade and were purchased from Fisher Scientific (St Louis, MO). Scintillant fluid was Ultima Flo M from Packard Instrument Co. (Meriden, CT). NuPage gels and reagents used in western immunoblot analysis were purchased from Novex (San Diego, CA). The primary antibodies for CYPs 2B1/2 and 3A1/2 were provided by Xenotech LLC (Kansas City, KS), whereas rabbit anti-CYP 1B1 (28,29) was generously supplied by Thomas Sutter (Johns Hopkins University, Baltimore, MD). The secondary antibody utilized for visualization of CYPs 2B1/2 and 3A1/2 was alkaline phosphatase-conjugated anti-rabbit IgG and was purchased from Southern Biotechnology Associates Inc. (Birmingham, AL). The BCIP/NBT phosphatase substrate was obtained from Kirkegaard Perry Laboratories (Gaithersburg, MD) and the PVDF membrane was from Millipore (Bedford, MA). Bound antibody against CYP 1B1 was detected with a horseradish peroxidase-conjugated donkey anti-rabbit IgG using the enhanced chemiluminescence method (Amersham Corp., Arlington Heights, IL).

Microsomal preparation

Where indicated, rats were treated with a s.c. cholesterol pellet with or without E2 (20 mg/pellet) for 1 week. Rats were anesthetized with CO₂, then killed by decapitation. The livers from 4–8 rats were pooled and homogenized in Tris-KCl buffer, pH 7.4, at 4°C. The homogenate was fractionated by differential centrifugation and the microsomal pellets were resuspended in phosphate/MgCl₂ buffer, pH 7.4, and stored at –80°C. Protein concentrations of the resulting rat liver microsomes (RLM) were determined using the Bradford reagent with bovine serum albumin as the standard.

Microsomal metabolism and analysis

[³H]E2 (0.1 μ Ci/incubation) or [¹⁴C]E2 (0.05 μ Ci/incubation) was mixed with unlabeled E2 and incubated with RLM in 50 mM Tris-HCl buffer, pH 7.4, containing 5 mM MgCl₂, 5 mM glucose 6-phosphate and 1 mM ascorbate at 37°C in a shaking water bath. E2 was added as a stock solution in DMSO, with a constant final concentration of 2% DMSO (v/v). The NADPH generating system, where used, included 1 U/ml glucose 6-phosphate dehydrogenase. Reactions were initiated by the addition of 1 mM NADP. Reactions with NADP and NAD as cofactors were initiated by addition of these compounds, to a final concentration of 1 mM, in the absence of glucose 6-phosphate dehydrogenase. Incubations were continued for 20 or 60 min as indicated, depending on substrate concentration. The reaction was stopped by extraction with 2 \times 3 vol ethyl acetate. Recoveries of labeled compounds by extraction were routinely >99%. The combined extracts were evaporated under vacuum and the residue dissolved in the initial acetonitrile/methanol/water/acetic acid mix for HPLC elution. Unlabeled estrogen metabolite standards were added to verify retention times. All incubations were performed in triplicate and data are presented as means \pm SD of three replicates.

HPLC analysis

Analysis of E2 metabolites was performed on a Supelcosil C18 column (5 μ m, 4.6 mm \times 25 cm) at 30°C (Supelco, Bellefonte, PA). The elution conditions were based on a system developed by Robert Breuggemeier (personal communication). A binary solvent gradient consisting of acetonitrile/methanol/water/acetic acid was used for elution of the compounds. Specifically, solvent A was 21% acetonitrile/22% methanol/57% water/0.1% acetic acid and solvent B was 40% acetonitrile/60% water/0.33% acetic acid. The gradient was as follows: 0–15 min 100% solvent A; a linear increase from 15–25 min to 19% solvent B; a linear increase from 25–35 min to 20% solvent B; a linear increase from 31–53 min to 100% solvent B; the column was returned to initial conditions over 20 min. Retention times for unlabeled metabolite standards, as detected by monitoring absorbance at 280 nm, were as follows: 6 α -OH-E2, 6.00 min; E3, 7.00 min; 4-OH-E2, 13.50 min; 2-OH-E2, 15.50 min; 2-OH-E1 and 4-OH-E1 co-eluted at 17.75 min; E2, 24.00 min; E1, 29.50 min. Radiolabeled metabolites were detected and quantified using a Packard Flo-One Beta detector with Ultima Flo M liquid scintillant. The limit of detection for individual metabolite peaks was ~0.3% of total substrate. Tabulated data represent means \pm SD from analysis of triplicate incubations.

Western immunoblot

Liver microsomes (50 μ g) were resolved by SDS-PAGE on 4–12% gradient NuPage gels in MOPS buffer. They were then transferred to a PVDF membrane (Immobilon-P; Millipore). Non-specific binding was blocked using Tris-buffered saline (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, containing 10% non-fat milk) for 1 h at room temperature. The membranes were probed for 2 h at room temperature with polyclonal antibodies for CYP 1B1, 2B1/2 and 3A1/2. Antibody binding for CYPs 2B1/2 and 3A1/2 was detected using alkaline phosphatase-conjugated anti-rabbit IgG, then visualized using BCIP/NBT phosphatase substrate. Anti-CYP 1B1 antibody was detected by incubation for 1 h with a horseradish peroxidase-linked donkey anti-rabbit IgG using the enhanced chemiluminescence method.

Results

Initial studies of the protein and time dependence of E2 metabolism by RLM from female ACI and Sprague-Dawley rats demonstrated a linear increase from 0.3 to 3.0 mg protein/ml and similar increases from 20 to 60 min incubation (data not shown). Based on these results, the experimental conditions were standardized to 1.0 mg protein/ml and 20 min incubation. Next, microsomes from ACI and Sprague-Dawley rats were incubated with a range of concentrations of E2 from 9 nM to 30 μ M, to characterize the dependence on substrate concentration. Striking quantitative and qualitative changes in metabolic profiles were observed as the E2 concentration was decreased.




Fig. 1. Estradiol metabolite profiles as a function of strain and estradiol concentration. [3 H]E2 was incubated with rat liver microsomes (1 mg microsomal protein/ml) for 20 min with a NADPH generating system. Ethyl acetate extracts were processed and analyzed by reverse phase HPLC as described in Materials and methods. These data were generated using RLM from mature rats. Similar results were obtained with immature animals.

These changes are demonstrated by the data in Figure 1, showing representative HPLC profiles resulting from E2 metabolism at the high and low ends of this concentration range.

With an initial concentration of 30 μ M E2 the major metabolite produced by RLM from both strains was E1, with minor amounts of 2-OH-E2 as the only other detectable product (Figure 1A and C). In the Sprague-Dawley preparation containing 9 nM E2 the major metabolite formed was still E1, but there was a nearly equal contribution of aromatic hydroxylation, specifically formation of 2-OH-E2 and 2/4-hydroxyestrone (CE1) (Figure 1B). A more dramatic change in metabolism was seen in the ACI RLM at nanomolar E2 concentrations (Figure 1D). At this E2 concentration E1 was no longer the major metabolite produced and instead aromatic hydroxylation was the major pathway. Moreover, the predominant catechol estrogen formed was 4-OH-E2, with lesser amounts of 2-OH-E2 and CE1 found. Examination of the kinetics of individual product formation at times from 5 to 20 min incubation showed that 2-OH-E2, 4-OH-E2 and E1 yields increased steadily with incubation time, whereas CE1 formation was only detectable after the 5 min incubation time (data not shown). This is consistent with their formation as primary and secondary metabolites of E2. Parallel incubations were performed with 3 H- and 14 C-labeled E2 at initial substrate concentrations of 0.3, 1 and 10 μ M, which produced identical

product distributions, demonstrating that loss of tritium was not a significant factor in our studies (data not shown).

This concentration-dependent shift in the spectrum of metabolites formed by RLM from each strain is shown by the tabulated product yields (Table I) and by the normalized product distributions (Figure 2). The E2 concentrations chosen for this experiment were 30 μ M, a concentration where E1 formation predominates, and 100 nM, where both strains produced significant yields of both dehydrogenation and hydroxylation products. At 30 μ M E2 the major metabolite produced for both strains and both age groups was E1, accounting for 55–95% of metabolites (Figure 2A). 2-OH-E2 is the next most abundant metabolite, ranging from 8% in immature ACI rats to >40% in mature Sprague-Dawley rats. The only group that produced detectable 4-OH-E2 at this E2 concentration was the mature ACI rats and this was <10% of total metabolites. At 100 nM E2, E1 remained the major product from Sprague-Dawley microsomes, but fell to 45% of total metabolites (Figure 2B). 2-OH-E2 production remained the same in each strain for each age when the E2 concentration was decreased. Also, at 100 nM E2 there was production of CE1 by all groups but immature ACI rats. Formation of the catechol estrones requires two oxidative steps, presumably the conversion of E2 to estrone followed by aromatic hydroxylation to the catechol. Our HPLC procedure could not resolve

Table I. Effects of strain and substrate concentration on estradiol product yields

| Strain | Age (weeks) | [E2] | 4-OH-E2 (pmol/mg/min) | 2-OH-E2 (pmol/mg/min) | CE1 (pmol/mg/min) | E1 (pmol/mg/min) |
|----------------|-------------|--------|-----------------------|-----------------------|-------------------|------------------|
| Sprague-Dawley | 7 | 100 nM | 0.10 ± 0.18 | 0.79 ± 0.07 | 0.39 ± 0.19 | 1.19 ± 0.26 |
| | 14 | 100 nM | <0.015 | 0.94 ± 0.07 | 0.60 ± 0.14 | 1.26 ± 0.04 |
| ACI | 7 | 100 nM | 2.79 ± 0.15 | 0.19 ± 0.17 | <0.015 | 0.97 ± 0.11 |
| | 14 | 100 nM | 1.66 ± 0.18 | 1.32 ± 0.09 | 0.72 ± 0.10 | 0.26 ± 0.04 |
| Sprague-Dawley | 7 | 30 µM | <4.5 | 28 ± 24 | <4.5 | 82 ± 6 |
| | 14 | 30 µM | <4.5 | 55 ± 6 | <4.5 | 75 ± 26 |
| ACI | 7 | 30 µM | <4.5 | 12 ± 16 | <4.5 | 251 ± 19 |
| | 14 | 30 µM | 51 ± 8 | 107 ± 14 | 20 ± 14 | 428 ± 25 |

Rat liver microsomes (1 mg/ml) were incubated for 20 min with the indicated concentrations of [³H]E2 with a NADPH generating system. All incubations were performed in triplicate. Extraction and HPLC analysis were as described under Materials and methods. Limits of detection for metabolites were 0.015 pmol/mg/min for 100 nM initial E2 concentration and 4.5 pmol/mg/min for 30 µM initial substrate concentration.





Fig. 2. Product distribution of estradiol metabolites from SD and ACI rat liver microsomes as a function of age and substrate concentration. The total metabolism for each condition, from Table I, was normalized to 1.0. Each incubation contained 1 mg/ml microsomal protein and was incubated with E2 for 20 min with a NADPH generating system. Extraction and analysis were as described under Materials and methods and for Figure 1. Data represent the means ± standard deviations from the analysis of three replicate incubations. Microsomes from immature (7-week-old) and mature (14-week-old) animals were examined in parallel incubations.




Fig. 3. Modulation of estradiol oxidation by ACI rat liver microsomes. RLM (1 mg/ml) were incubated for 20 min with 1 µM [³H]E2 with either a NADPH generating system or initiation by addition of 1 mM NAD or NADP. Clotrimazole was added 10 min prior to the initiation of reactions. Extraction and analysis were as described under Materials and methods and for Figure 1. Data represent the means ± standard deviations from the analysis of three replicate incubations. Comparison of the rate of individual metabolite formation to the rate observed with the NADPH generating system was performed by one-way ANOVA followed by Dunnett's test. *, Significant difference from NADPH generating system, *P* < 0.05.

the catechol estrones 2-OH-E1 and 4-OH-E1, but it could distinguish the catechol estrones from the catechol estradiols 2-OH-E2 and 4-OH-E2. Strikingly, at 100 nM E2 RLM from both age groups of ACI rats produced more 4-OH-E2 than any other metabolite, accounting for 35% of metabolites in mature ACI rats and 70% of metabolites formed in immature ACI rats. It is key to note that the clear qualitative differences in metabolite profile for E2 oxidation are between strains and that only minor quantitative differences are observed between immature and mature female rats of the same strain.

The ACI preparations were incubated with various cofactors and inhibitors to determine what enzymes or families of enzymes were responsible for E2 metabolism (Figure 3). We chose 1 µM E2 as the initial substrate concentration to ensure significant production of E1 and of both aromatic hydroxylation products. Incubations containing the standard NADPH generating system were used as a control. The major metabolite produced by ACI liver microsomes was 4-OH-E2, with lesser amounts of 2-OH-E2 and E1 being formed. Incubations of 1 µM E2 with ACI RLM with the NADPH generating system and 10 µM clotrimazole, a broad CYP inhibitor, showed a

Table II. Kinetic constants for microsomal estradiol oxidation

| Metabolite | Sprague-Dawley | | ACI | |
|--------------|---------------------|----------------------------|---------------------|----------------------------|
| | K_m (μ M) | V_{max} (pmol/mg/min) | K_m (μ M) | V_{max} (pmol/mg/min) |
| 4-Hydroxy-E2 | ND | ND | 0.8 ± 0.3 | 19.0 ± 2.0 |
| 2-Hydroxy-E2 | 3.3 ± 1.3 | 5.8 ± 1.8 | 4.2 ± 0.8 | 34.0 ± 2.0 |
| E1 | 14.8 ± 0.8 | 386 ± 19 | 38.0 ± 2.0 | 414 ± 12 |

Rat liver microsomes (1 mg/ml) were incubated for 20 min with concentrations of [3 H]E2 at half-log intervals from 9 nM to 30 μ M with a NADPH generating system. All incubations were performed in triplicate. Extraction and HPLC analyses were as described under Materials and methods. Kinetic constants were derived from the data using the kinetics analysis program GraFit v.4.0. ND, not detected. Limit of detection for individual products was 0.3% of the initial E2 concentration and thus ranged from 0.0014 pmol/mg/min at 9 nM substrate to 4.5 pmol/mg/min at 30 μ M E2.

75% decrease in production of 4-OH-E2 and 2-OH-E2, indicating that these are products of CYP-dependent reactions. Also, there was an increase in E1 production, a 17 β -hydroxysteroid dehydrogenase (17 β -HSD)-dependent reaction. When the cofactor NADP was added without glucose 6-phosphate dehydrogenase there was a 70% decrease in production of 4-OH-E2 and 2-OH-E2, with a corresponding increase in E1 production. This is consistent with the ability of NADP to serve as a cofactor for 17 β -HSD (30,31) but not for CYP-dependent hydroxylation. There was some production of 4-OH-E2 and 2-OH-E2, which could be attributed to reduction of the NADP to NADPH by 17 β -HSD or other microsomal dehydrogenases, which could then serve as a cofactor for CYP-dependent metabolism of E2 to the catechols. When NAD, a cofactor that cannot be reduced to NADPH, was added there was complete abolition of formation of the catechol estrogens.

The differences in hydroxylation products formed in the two strains of rats suggests that there are different CYPs present in liver microsomes from these two strains. Different enzymes might be expected to exhibit different kinetic constants. Sprague-Dawley and ACI RLM were incubated for 20 min with E2 concentrations of 0.003, 0.01, 0.03, 0.10, 0.30, 1, 3, 10, 30 and 60 μ M. Using graphical analysis of initial rate data, kinetic constants were obtained for the three metabolites of interest for ACI and Sprague-Dawley rats (Table II). Catechol estrones, which result from two sequential enzymatic reactions, were not included in the calculation of initial rate, either as distinct products or as contributors to either aromatic hydroxylation or dehydrogenation. We found that the V_{max} and K_m for E1 in both rat strains are significantly higher than for aromatic hydroxylation. This is consistent with the known properties of 17 β -HSD, a high capacity and relatively high K_m enzyme for E2 oxidation. Aromatic hydroxylation, however, is catalyzed by CYPs. Second, there is no significant difference between the E2 K_m value for 2-hydroxylation in Sprague-Dawley and ACI rats. In contrast, the E2 K_m value for 4-hydroxylation in ACI rats is significantly lower than the K_m for 2-hydroxylation in ACI rats. These data suggest that the same CYP may catalyze 2-hydroxylation of E2 in both strains, but that the 4-hydroxylation seen with ACI RLM is catalyzed by a different enzyme.

The search for this different CYP-dependent enzyme was carried out by western analysis of RLM. Immunoblot analysis




Fig. 4. Western analysis of cytochrome P450 expression in rat liver microsomes. Rat liver microsomes (50 μ g) were resolved by SDS-PAGE on 4–12% gradient gels, transferred to a PVDF membrane and probed with polyclonal antibodies for CYPs 2B1/2 and 3A1/2 for 2 h at room temperature. Antibody reactions were detected using alkaline phosphatase-conjugated anti-rabbit IgG, then visualized using BCIP/NBT phosphatase substrate. SD, Sprague-Dawley; C, control; E2, 17 β -estradiol-treated; 6 wk, sexually immature animals; 12 wk, sexually mature animals.

was performed on the microsomal fractions of each rat strain and each age group to determine the expression level of CYPs known to be involved in E2 metabolism. Under the conditions studied there is expression of CYPs 2B1/2 and 3A1/2 in both strains of rat (Figure 4). There are no major differences in the expression of CYP 2B1/2 or 3A1/2 between the two age groups of ACI rats. Both immature and mature Sprague-Dawley rats express comparable levels of CYP 2B1/2, but immature Sprague-Dawley rats have diminished 3A1/2 expression relative to mature rats. In this study we also examined the effect of chronic E2 administration on hepatic CYP expression. No effects were detected. This was mirrored by a lack of detectable effect of E2 treatment on the ability of RLM to metabolize E2 (data not shown). ACI and Sprague-Dawley RLM were analyzed for expression of CYP 1B1 as well. There was no detectable expression of CYP 1B1, a known estradiol 4-hydroxylase, in RLM from either strain of rat (data not shown).

Discussion

We have demonstrated that liver microsomes from ACI and Sprague-Dawley rats both efficiently metabolize E2 over a wide range of initial substrate concentrations. These liver preparations catalyze only aromatic hydroxylation and the 17 β -dehydrogenation of E2. This is in marked contrast to male Sprague-Dawley liver microsomes, which yield a far more complex mixture of oxidized metabolites (G.A.Reed, unpublished observation; 32). Similar metabolite profiles are produced by RLM from females of the two strains at high initial E2 concentrations (i.e. ≥ 10 μ M), but this changes dramatically when the substrate concentration is lowered into the nanomolar range. Sprague-Dawley rats yield more 2-OH-E2 relative to E1 as the initial substrate concentration is decreased, but E1 remains the major product. In ACI rats, however, aromatic hydroxylation dominates and 4-OH-E2 is produced as the predominant metabolite at lower E2 concentrations.

Previous reports on the metabolism of E2 by microsomal preparations and by purified CYPs have employed extremely high substrate concentrations, ranging from 20 to 200 μ M (32–34; reviewed in ref. 35). Our qualitative findings at high E2 concentrations, i.e. that E1 is the major metabolite formed followed by 2-OH-E2, are consistent with other laboratories

studying E2 metabolism by RLM from female Sprague-Dawley rats and from other strains as well (33,34). With microsomes from the ACI rat, however, this qualitative result changes dramatically, but only when the initial E2 concentration is lowered toward more realistic levels. We have shown that rat liver microsomes oxidize E2 at low concentrations, nearing actual physiological concentrations. These lower, more physiologically relevant concentrations, which have not been examined before, were required in order to observe the dramatic differences in metabolite profiles between these two rat strains.

In rats hepatic hydroxylation of E2 to the catechols 2-OH-E2 and 4-OH-E2 is catalyzed by CYPs 1A2, 2B1/2, 2C6, 2C11, the 2D family and the 3A family (reviewed in 11,35). Production of 2-OH-E2 by these CYPs greatly exceeds formation of 4-OH-E2, with 80–90% production of 2-OH-E2 and only 10–20% production of 4-OH-E2. This greater production of 2-OH-E2 reflects the orientation of E2 in the active site of the enzyme. Thus, formation of more 2-OH-E2 than 4-OH-E2 is a consequence of the binding interaction between substrate and CYP and should not be dependent on the concentration of E2. In contrast, human CYP 1B1 is unique in that it is reported to be a specific 4-hydroxylase of E2 (36). The presence of CYP 1B1 as a constitutive enzyme in female ACI rat liver would be consistent with our observed metabolite profile. By comparing the K_m values determined for ACI RLM, it is apparent that 4-hydroxylation of E2 is catalyzed by a different enzyme with a lower K_m than that for 2-hydroxylation. The K_m determined for 4-hydroxylation of E2 in ACI RLM, substantially lower than that determined for 2-hydroxylation of E2 in the same incubations, matches the reported E2 K_m value for 4-hydroxylation by recombinant human CYP 1B1 (36), providing an additional suggestion that this CYP may be responsible for the observed biotransformation of E2.

We found, however, that in female ACI rat liver there are no qualitative differences in the CYPs tested from what is expressed in the Sprague-Dawley female liver. There was expression of CYPs 2B1/2 and 3A1/2 but no detectable expression of CYP 1B1 in microsomes from either strain of rat. This suggests that 4-OH-E2 formation in ACI rats is due either to an additional CYP not probed for or a polymorphism in an existing CYP that alters the site of E2 hydroxylation. This latter proposal is particularly interesting in the light of a recent report from Shimada *et al.* (37). They characterized polymorphic human CYP 1B1 variants and found that these variants altered the ratio of 4-hydroxylation to 2-hydroxylation of E2 catalyzed by these enzymes. This subtle modulation of the orientation of E2 in the active site of a CYP and the resultant alteration in the site selectivity for E2 hydroxylation is precisely what we believe is responsible for the different metabolite distribution produced by ACI as opposed to Sprague-Dawley liver.

The proposed mechanisms for the carcinogenic action of estrogens depend on either estrogenicity or reactivity of the active species and both can be modulated by oxidative metabolism of estrogens. 2-OH-E2 has a lower affinity for the estrogen receptor (38,39) and has lower estrogenicity than the parent hormone E2 (40,41). Rapid *O*-methylation of 2-OH-E2 by catechol *O*-methyltransferase (COMT) results in a more rapid clearance *in vivo* and may also result in product inhibition of tumor cell proliferation (42,43). The resulting *O*-methylation of 2-OH-E2 may be the reason for its lack of carcinogenicity. 4-OH-E2, however, is a carcinogenic metabolite of E2 (44,45). It binds to the estrogen receptor with a similar affinity to E2

and it also activates the estrogen receptor (38). 4-OH-E2 takes longer to dissociate from the estrogen receptor compared with E2, therefore, there could be increased biological effects of 4-OH-E2 in comparison with E2 (46). COMT-catalyzed *O*-methylation is inhibited by 4-OH-E2. Regardless of the mechanism, 4-OH-E2 is important in the carcinogenicity of E2. It is not surprising that ACI rats, which are more sensitive to E2 as a mammary carcinogen, produce more of this detrimental metabolite 4-OH-E2 than Sprague-Dawley rats at near physiological levels of substrate.

Liver metabolism of E2 is an important first step in understanding the role of metabolism in mammary carcinogenesis. The liver plays a role in controlling the systemic levels of circulating metabolites. In addition to the liver, however, there is much interest in the metabolism of E2 in target tissues (35). Our next goal is to investigate the metabolism of E2 in the mammary gland to see whether there are differences in the target tissue that may be responsible for the differences in susceptibility of the two strains of rat. If there are differences in metabolism in the target tissue (the mammary gland) this would provide additional support for the role of metabolism of E2 in carcinogenicity.

In summary, these results reveal that there are dramatic differences in the hepatic metabolism of E2 in ACI and Sprague-Dawley rats and that these differences are only apparent as the conditions approach physiological concentrations of E2. Since 4-OH-E2 is thought to be the main carcinogenic metabolite of E2, it is even more interesting that ACI rat liver produces primarily this metabolite when challenged with near physiological levels of E2. The exclusive formation of this metabolite by the rat strain which is more sensitive to the carcinogenic effects of E2 suggests a role for this difference in E2 disposition in the different responses of the strains.

Acknowledgements

Western analysis for CYP 1B1 was performed by Nigel Walker (National Institute for Environmental Health Sciences, Research Triangle Park, NC). This work was supported by the US Army Breast Cancer Research Program (DAMD17-1-7155) and by NIH ES-07079.

References

1. Henderson,B.E., Ross,R. and Bernstein,L. (1988) Estrogens as a cause of human cancer: the Richard and Linda Rosenthal Foundation Lecture. *Cancer Res.*, **48**, 246–253.
2. Bernstein,L. and Ross,R.K. (1993) Endogenous hormones and breast cancer risk. *Epidemiol. Rev.*, **15**, 48–65.
3. Adami,H.-O., Persson,I., Ekblom,A., Ponten,J. and Trichopoulos,D. (1995) The aetiology and pathogenesis of human breast cancer. *Mutat. Res.*, **333**, 29–35.
4. Kelsey,J.L., Gammon,M.D. and John,E.M. (1993) Reproductive factors and breast cancer. *Epidemiol. Rev.*, **15**, 36–47.
5. Layde,P.M. and Webster,L.A., Baughman,A.L., Wingo,P.A., Rubin,G.L. and Ory,H.W. (1989) The independent associations of parity, age at first full term pregnancy and duration of breastfeeding with the risk of breast cancer. Cancer and Steroid Hormone Study Group. *J. Clin. Epidemiol.*, **42**, 963–973.
6. Bernstein,L., Pike,M.C., Ross,R.K., Judd,H.L., Brown,J.B. and Henderson,B.E. (1985) Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. *J. Natl Cancer Inst.*, **74**, 741–745.
7. Gapstur,S.M., Morrow,M. and Sellers,T.A. (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology. *J. Am. Med. Assoc.*, **281**, 2091–2097.
8. Li,J.J. and Li,S.A. (1996) The effects of hormones on tumor induction. In Arcos,J.C., Argus,M.S. and Woo,Y.Y. (eds), *Chemical Induction of Cancer*. Birkhauser Press, Boston, MA, pp. 397–449.

9. Russo, J., Gusterson, B.A., Rogers, A.E., Russo, I.H., Weelings, S.R. and Van Zweiten, M.J. (1990) Biology of disease. Comparative study of human and rat mammary tumorigenesis. *Lab. Invest.*, **62**, 244–278.
10. Shull, J.D., Spady, T.J., Snyder, M.C., Johansson, S.L. and Pennington, K.L. (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17 β -estradiol rapidly develop mammary carcinoma. *Carcinogenesis*, **18**, 1595–1601.
11. Yager, J.D. and Liehr, J.G. (1996) Molecular mechanisms of estrogen carcinogenesis. *Annu. Rev. Pharmacol. Toxicol.*, **36**, 203–232.
12. Wendell, D.L., Herman, A. and Gorski, J. (1996) Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor. *Proc. Natl Acad. Sci. USA*, **93**, 8112–8116.
13. International Agency for Research on Cancer (1979) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals in Humans*, Vol. 21, *Sex Hormones (II)*. IARC, Lyon, pp. 173–231.
14. McKenzie, K. and Sukumar, S. (1994) Molecular mechanisms of chemical carcinogenesis in rodent models. In Dickson, R. and Lippman, M. (eds), *Mammary Tumorigenesis and Malignant Progression*. Kluwer Academic Publishers, New York, NY, pp. 313–329.
15. Gladek, A. and Liehr, J.G. (1989) Mechanism of genotoxicity of diethylstilbestrol *in vivo*. *J. Biol. Chem.*, **264**, 16847–16852.
16. Roy, D. and Liehr, J.G. (1999) Estrogen, DNA damage and mutations. *Mutat. Res.*, **424**, 107–115.
17. Epe, B., Schiffmann, D. and Metzler, M. (1986) Possible role of oxygen radicals in cell transformation by diethylstilbestrol and related compounds. *Carcinogenesis*, **7**, 1329–1334.
18. Rosier, J.A. and Van Peteghem, C.H. (1989) Peroxidative *in vitro* metabolism of diethylstilbestrol induces formation of 8-hydroxy-2'-deoxyguanosine. *Carcinogenesis*, **10**, 405–406.
19. Barrett, J.C., Wong, A. and McLachlan, J.A. (1981) Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. *Science*, **212**, 1402–1404.
20. Tsutsui, T., Suzuki, N., Fukuda, S., Sato, M., Maizumi, H., McLachlan, J.A., Barrett, J.C. (1987) 17 β -Estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. *Carcinogenesis*, **8**, 1715–1719.
21. Aizu-Yokota, E., Susaki, A. and Sato, Y. (1995) Natural estrogens induce modulation of microtubules in Chinese hamster V79 cell in culture. *Cancer Res.*, **55**, 1863–1868.
22. Dunning, W.F. and Curtis, M.R. (1952) The incidence of diethylstilbestrol-induced cancer in reciprocal F1 hybrids obtained from crosses between rats of inbred lines that are susceptible and resistant to the induction of mammary cancer by this agent. *Cancer Res.*, **12**, 702–706.
23. Dunning, W.F. (1953) Strains differences in response to estrone and induction of mammary gland, adrenal and bladder cancer in rats. *Cancer Res.*, **13**, 147–152.
24. Stone, J.P., Holtzman, S. and Shellabarger, C.J. (1979) Neoplastic responses and correlated plasma prolactin levels in diethylstilbestrol-treated ACI and Sprague-Dawley rats. *Cancer Res.*, **39**, 773–778.
25. Sydnor, K.L., Butendandt, O., Brillantes, F.P. and Huggins, C. (1962) Race-strain factor related to hydrocarbon-induced mammary cancer in rats. *J. Natl Cancer Inst.*, **29**, 805–814.
26. Shellabarger, C.J., McKnight, B., Stone, J.P. and Holtzman, S. (1980) Interaction of dimethylbenzanthracene and diethylstilbestrol on mammary adenocarcinoma formation in female ACI rats. *Cancer Res.*, **40**, 1808–1811.
27. Isaacs, J.T. (1988) Inheritance of a genetic factor from the Copenhagen rat and the suppression of chemically-induced mammary adenocarcinogenesis. *Cancer Res.*, **48**, 2204–2213.
28. Walker, N.J., Crofts, F.G., Li, Y., Lax, S.F., Hayes, C.L., Strickland, P.T., Lucier, G.W. and Sutter, T.R. (1998) Induction and localization of cytochrome P450 1B1 (CYP1B1) in the livers of TCDD-treated rats: detection using polyclonal antibodies raised to histidine tagged fusion proteins produced and purified from bacteria. *Carcinogenesis*, **19**, 395–402.
29. Walker, N.J., Portier, C.J., Lax, S.F., Crofts, F.G., Li, Y., Lucier, G.W. and Sutter, T.R. (1999) Characterization of the dose-response of CYP1B1, CYP1A1 and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicol. Appl. Pharmacol.*, **154**, 279–286.
30. Ghraf, R., Raible, M. and Schriefers, H. (1973) 11 β - and 17 β -hydroxysteroid dehydrogenase activity of rat liver: intracellular localization and sex differentiation. *Hoppe-Seyler's Z. Physiol. Chem.*, **354**, 299–305.
31. Ghraf, R., Vetter, U., Zandveld, J.M. and Schriefers, H. (1975) Organ-specific ontogeneses of steroid hormone metabolizing enzyme activities in the rat. *Acta Endocrinol. (Copenh.)*, **79**, 192–201.
32. Suchar, L.A., Chang, R.L., Rosen, R.T., Lech, J. and Conney, A.H. (1995) High-performance liquid chromatography separation of hydroxylated estradiol metabolites: formation of estradiol metabolites by liver microsomes from male and female rats. *J. Pharmacol. Exp. Ther.*, **272**, 197–206.
33. Ball, S.E., Forrester, L.M., Wolf, C.R. and Back, D.J. (1990) Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α -ethinyloestradiol. *Biochem. J.*, **267**, 221–226.
34. Suchar, L.A., Chang, R.L., Thomas, P.E., Rosen, R.T., Lech, J. and Conney, A.H. (1996) Effects of phenobarbital, dexamethasone and 3-methylcholanthrene administration on the metabolism of 17 β -estradiol by liver microsomes from female rats. *Endocrinology*, **137**, 663–676.
35. Zhu, B.T. and Conney, A.H. (1998) Functional role of estrogen metabolism in target cells: review and perspectives. *Carcinogenesis*, **19**, 1–27.
36. Hayes, C.L., Spink, D.C., Spink, B.C., Cao, J.Q., Walker, N.J. and Sutter, T.R. (1996) 17 β -Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. *Proc. Natl Acad. Sci. USA*, **93**, 9776–9781.
37. Shimada, T., Watanabe, J., Kawagiri, K., Sutter, T.R., Guengerich, F.P., Gillam, E.M.J. and Inoue, K. (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. *Carcinogenesis*, **20**, 1607–1613.
38. MacLusky, N.J., Barnea, E.R., Clark, C.R. and Naftolin, F. (1983) Catechol estrogens and estrogen receptors. In Merriam, G.R. and Lipsett, M.B. (eds), *Catechol Estrogens*. Raven, New York, NY, pp. 151–165.
39. Feigelson, H.S. and Henderson, B.E. (1996) Estrogens and breast cancer. *Carcinogenesis*, **17**, 2279–2284.
40. Martucci, C. and Fishman, J. (1979) Impact of continuously administered catechol estrogens on uterine growth and LH secretion. *Endocrinology*, **105**, 1288–1292.
41. Fishman, J. (1981) Biological action of catecholestrogens. *J. Endocrinol.*, **85**, 59P–69P.
42. Seegers, J.C., Aveling, M.-L., van Aswegen, C.H., Cross, M., Koch, F. and Joubert, W.S. (1989) The cytotoxic effects of estradiol-17 β , catecholestrodiols and methoxyestrodiols on dividing MCF-7 and Hela cells. *J. Steroid Biochem.*, **32**, 797–809.
43. Lottering, M.-L., Haag, M. and Seegers, J.C. (1992) Effects of 17 β -estradiol metabolites on cell cycle events in MCF-7 cells. *Cancer Res.*, **52**, 5926–5932.
44. Weisz, J., Bui, Q.D., Roy, D. and Liehr, J.G. (1992) Elevated 4-hydroxylation of estradiol by hamster kidney microsomes: a potential pathway of metabolic activation of estrogens. *Endocrinology*, **131**, 655–661.
45. Liehr, J.G. and Ricci, M.J. (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. *Proc. Natl Acad. Sci. USA*, **93**, 3294–3296.
46. Barnea, E.R., MacLusky, N.J. and Naftolin, F. (1983) Kinetics of catecholestrogen-estrogen receptor dissociation: a possible factor underlying differences in catecholestrogen biological activity. *Steroids*, **41**, 643–656.

Received July 26, 2000; revised September 28, 2000;
accepted October 3, 2000